Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery

Last updated: July 12, 2016
Sponsor: American University of Beirut Medical Center
Overall Status: Completed

Phase

2/3

Condition

Diabetic Foot Ulcers

Diabetic Vitreous Hemorrhage

Diabetic Retinopathy

Treatment

N/A

Clinical Study ID

NCT02213159
ANES.CZ.2
  • Ages 18-70
  • All Genders

Study Summary

The purpose of this study is to determine if Dexmedetomidine given at the end of surgery will reduce postoperative morphine consumption and improve postoperative quality of recovery as compared to morphine in patients undergoing laparoscopic bariatric surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Body Mass Index > 40 kg/m2 or BMI > 35 kg/m2 with comorbid conditions such ashypertension, diabetes or sleep apnea

  • American Society of Anesthesiologists class I or II

  • Undergoing laparoscopic sleeve gastrectomy bariatric surgery

Exclusion

Exclusion Criteria:

  • Allergy to morphine or its derivatives

  • Allergy to α-2 adrenergic agonists

  • weight over 180 kg

  • history of uncontrolled hypertension

  • heart block greater than first degree

  • prolonged QT interval

  • clinically significant neurologic, cardiovascular, renal, hepatic, or gastrointestinaldiseases

  • received an opioid analgesic medication within a 24 h period prior to surgery

  • history of alcohol, drug abuse or chronic opioid intake

  • history of psychiatric disorder

  • pregnant or breastfeeding.

Study Design

Total Participants: 60
Study Start date:
July 01, 2014
Estimated Completion Date:
December 31, 2015

Study Description

effect of Dexmedetomidine bolus on postoperative morphine requirements

Connect with a study center

  • American University of Beirut Medical Center

    Beirut,
    Lebanon

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.